ONCOLYTICS BIOTECH INC. Increase Through New Leases Liabilities Arising From Financing Activities
ONCOLYTICS BIOTECH INC. (ONCY) reported Increase Through New Leases Liabilities Arising From Financing Activities of CAD 785.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-03-07.
Financial Statements › Cash Flow › Financing Activities
ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities · last filed 2025-03-07
USD
| Period end | Increase Through New Leases Liabilities Arising From Financing Activities 12 month | Increase Through New Leases Liabilities Arising From Financing Activities 12 month as first filed |
|---|---|---|
| 2022-12-31 | $0.00 20-F · filed 2023-03-03 | |
| 2021-12-31 | $203.00K 20-F · filed 2023-03-03 | $203.87K 20-F · filed 2022-03-03 |
| 2020-12-31 | $297.37K 20-F · filed 2022-03-03 |
CAD
| Period end | Increase Through New Leases Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2024-12-31 | 785.00K CAD 20-F · filed 2025-03-07 |
| 2023-12-31 | 392.00K CAD 20-F · filed 2025-03-07 |
| 2022-12-31 | 0.00 CAD 20-F · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |